Skip to main content
Equibles
NXTC logo

NXTC · NextCure, Inc.

Track NXTC — free

Use NXTC with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$7.68 -0.14 (-1.79%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 6, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Our expectation to incur additional operating losses and negative operating cash flows in the future and the need for additional funding to support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that these unaudited financial statements are issued.”
View the 10-Q filed Aug 6, 2026
Market Cap
$35.79M
Shares
4.58M

NXTC metrics

59 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$7.82
Market cap
$35.79M

Price action

19 metrics
Price change (1W)
+28.4%
Price change (30D)
+14.3%
Price change (3M)
+165.1%
Price change (6M)
-36.9%
Price change (YTD)
-44.9%
Price change (1Y)
+58.3%
Trailing year
Price change (5Y)
—
52-week high
$14.27
52-week low
$1.60
Change from 52-week high
-45.2%
Change from 52-week low
+388.8%
Annualized volatility
241.2%
Beta
2.1
RSI (14D)
65.5
Price vs SMA 50
+51.1%
Price vs SMA 200
-14.0%
Avg volume (3M)
2.12M
Relative volume
0.0
Average dollar volume
$13.58M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
4.58M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.7×
reciprocal yield 142.2%
EV / EBITDA
—
EV / EBIT
—
P / sales
1.5×
reciprocal yield 68.1%
P / book
2.9
reciprocal yield 33.9%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-119.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
47.9×
reciprocal yield 2.1%
EV / revenue historical average (5Y)
47.9×
reciprocal yield 2.1%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2021-03-04

Profitability

9 metrics
Gross margin
—
Operating margin
-184.2%
Trailing 12 months
Net margin
-163.6%
Gross profit (TTM)
—
Operating profit (TTM)
−$43.90M
Net income (TTM)
−$42.75M
Trailing 12 months
Diluted EPS (TTM)
$-8.33
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-409.75

Growth

11 metrics
Revenue growth YoY
+1,549.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$24.38M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+123.6%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-351.9%
Return on assets
-189.0%
Debt / equity
—
Current ratio
3.5
EBITDA (TTM)
−$63.86M
Free cash flow (TTM)
—
Quick ratio
3.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$15.26M
Total assets
$22.62M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$36.98M
Capital expenditures (TTM)
$521,000
R&D (TTM)
$27.20M
SG&A (TTM)
—
Stock compensation (TTM)
$1.68M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
30
13F filer change QoQ
+4
Institutional ownership
37.9%

Short interest

3 metrics
Short interest
3.2%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
64 / 100

Insider activity

2 metrics
Net insider buying (90D)
$1.53M
Insider-sentiment score
87 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1661059 CUSIP 65343E207 13F (30d) 27 filings 27 filers Visit website Investor relations